India, June 23 -- Boundless Bio, Inc. (BOLD) and Serapha Bio on Tuesday announced a definitive merger agreement under which Serapha Bio, Inc. will combine with Boundless Bio in an all-stock transaction.
The transaction is expected to close in the fourth quarter of 2026.
The combined company's cash balance, including proceeds from the private placement, is expected to fund operations into the second half of 2029.
Upon completion of the merger, the combined company will operate as Serapha Bio and is expected to trade on Nasdaq under the ticker symbol AATD.
The companies also announced a concurrent private placement of approximately $230 million co-led by RTW Investments and RA Capital Management.
googletag.cmd.push(function() { googletag...